Understanding reduced rotavirus vaccine efficacy in low socio-economic settings

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Lopman, Benjamin A ^a   Pitzer, Virginia E ^b,c   Sarkar, Rajiv ^d   Gladstone, Beryl ^d   Patel, Manish ^a   Glasser, John ^a   Gambhir, Manoj ^a,e   Atchison, Christina ^f   Grenfell, Bryan T ^b,c   Edmunds, W John ^f   Kang, Gagandeep ^e   Parashar, Umesh D ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d CHRISTIAN MEDICAL COLLEGE   (India)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTRINSIC FACTOR; ROTAVIRUS VACCINE;

ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; GASTROENTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LIFE EXPECTANCY; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; ROTAVIRUS; ROTAVIRUS INFECTION; SOCIAL STATUS; VACCINATION;

AGE DISTRIBUTION; CHILD, PRESCHOOL; ENGLAND; GASTROENTERITIS; HUMANS; INCIDENCE; INDIA; INFANT; INFANT, NEWBORN; MEXICO; MODELS, BIOLOGICAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

ROTAVIRUS;

EID: 84864721137     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041720     Document Type: Article

References (41)

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, et al. ((2010)) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375:1969-1987.
2. Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, et al. ((2012)) 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 12:136-141.
3. World Health Organization ((2009)) Rotavirus vaccines:an update. Wkly Epidemiol Rec 84:533-540.
4. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, et al. ((2010)) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 376:615-623.
5. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, et al. ((2010)) Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 362:289-298.
6. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, et al. ((2010)) Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet 376:606-614.
7. Nelson EA, Glass RI, ((2010)) Rotavirus: realising the potential of a promising vaccine. Lancet 376:568-570.
8. Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, et al. ((2010)) Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 125:e199-207.
9. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, et al. ((2011)) Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 30:S25-29.
10. Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang XL, et al. ((2006)) Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J Infect Dis 194:370-376.
11. Boom JA, Tate JE, Sahni LC, Rench MA, Hull JJ, et al. ((2010)) Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 125:e199-207.
12. Buttery JP, Lambert SB, Grimwood K, Nissen MD, Field EJ, et al. ((2011)) Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 30:S25-29.
13. Linhares AC, Velazquez FR, Perez-Schael I, Saez-Llorens X, Abate H, et al. ((2008)) Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study. Lancet 371:1181-1189.
14. Pasetti MF, Simon JK, Sztein MB, Levine MM, ((2009)) Immunology of gut mucosal vaccines. Immunol Rev 239:125-148.
15. John TJ, Jayabal P, ((1972)) Oral polio vaccination of children in the tropics. I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 96:263-269.
16. Grassly NC, Fraser C, Wenger J, Deshpande JM, Sutter RW, et al. ((2006)) New strategies for the elimination of polio from India. Science 314:1150-1153.
17. Lagos R, Fasano A, Wasserman SS, Prado V, San Martin O, et al. ((1999)) Effect of small bowel bacterial overgrowth on the immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR. J Infect Dis 180:1709-1712.
18. Cooper PJ, Chico ME, Losonsky G, Sandoval C, Espinel I, et al. ((2000)) Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR. J Infect Dis 182:1199-1206.
19. Ahmed T, Arifuzzaman M, Lebens M, Qadri F, Lundgren A, ((2009)) CD4+ T-cell responses to an oral inactivated cholera vaccine in young children in a cholera endemic country and the enhancing effect of zinc supplementation. Vaccine 28:422-429.
20. Santos N, Hoshino Y, ((2005)) Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol 15:29-56.
21. Moon SS, Wang Y, Shane AL, Nguyen T, Ray P, et al. ((2010)) Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 29:919-923.
22. Atchison C, Lopman B, Edmunds WJ, ((2010)) Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 28:3118-3126.
23. Ruuska T, Vesikari T, ((1990)) Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 22:259-267.
24. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, et al. ((1996)) Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 335:1022-1028.
25. Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, et al. ((2011)) Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 365:337-346.
26. Halloran ME, Haber M, Longini IM Jr, ((1992)) Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol 136:328-343.
27. Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, et al. ((2009)) Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis 200 Suppl 1: S39-48.
28. Phillips G, Tam CC, Conti S, Rodrigues LC, Brown D, et al. ((2010)) Community Incidence of Norovirus-associated Infectious Intestinal Disease in England: Improved Estimates Using Viral Load for Norovirus Diagnosis. Am J Epidemiol.
29. Moon SS, Wang Y, Shane AL, Nguyen T, Ray P, et al. ((2010)) Inhibitory effect of breast milk on infectivity of live oral rotavirus vaccines. Pediatr Infect Dis J 29:919-923.
30. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, et al. ((2006)) Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 354:11-22.
31. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, et al. ((2006)) Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23-33.
32. Field EJ, Vally H, Grimwood K, Lambert SB, ((2010)) Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 126:e506-512.
33. Braeckman T, Van Herck K, Raes M, Vergison A, Sabbe M, et al. ((2011)) Rotavirus vaccines in Belgium: policy and impact. Pediatr Infect Dis J 30:S21-24.
34. Sahni LC, Boom JA, Patel MM, Baker CJ, Rench MA, et al. ((2010)) Use of an immunization information system to assess the effectiveness of pentavalent rotavirus vaccine in US children. Vaccine 28:6314-6317.
35. de Palma O, Cruz L, Ramos H, de Baires A, Villatoro N, et al. ((2010)) Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 340:c2825.
36. Justino MC, Linhares AC, Lanzieri TM, Miranda Y, Mascarenhas JD, et al. ((2011)) Effectiveness of the Monovalent G1P[8] Human Rotavirus Vaccine Against Hospitalization for Severe G2P[4] Rotavirus Gastroenteritis in Belem, Brazil. Pediatr Infect Dis J.
37. Correia JB, Patel MM, Nakagomi O, Montenegro FM, Germano EM, et al. ((2011)) Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 201:363-369.
38. Patel M, Pedreira C, De Oliveira LH, Tate J, Orozco M, et al. ((2009)) Association between pentavalent rotavirus vaccine and severe rotavirus diarrhea among children in Nicaragua. JAMA 301:2243-2251.
39. Farrington CP, ((1992)) The measurement and interpretation of age-specific vaccine efficacy. Int J Epidemiol 21:1014-1020.
40. Mossong J, Hens N, Jit M, Beutels P, Auranen K, et al. ((2008)) Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 5:e74.
41. Bhandari N, Sharma P, Taneja S, Kumar T, Rongsen-Chandola T, et al. ((2009)) A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis 200:421-429.